BOCA RATON, Fla., March 3 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Thomas H. McLain,
chairman, chief executive officer and president, will be presenting at the
Lehman Brothers Ninth Annual Global Healthcare Conference on March 9, 2006, at
8:30 am ET at the Loews Miami Beach Hotel, Poinciana 4 Room, 1601 Collins
Avenue, Miami Beach, Florida. Mr. McLain will present a company overview, and
Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and
regulatory affairs, will speak about Civacir(R) [Hepatitis C Immune Globulin
(Human)], the company's investigational human polyclonal antibody product that
contains antibodies to hepatitis C virus (HCV). Civacir is being developed to
prevent hepatitis C disease in HCV-positive liver transplant patients and is
being evaluated for the treatment of chronic hepatitis C virus infections.
Civacir has received Orphan Drug Designation from the U.S. Food and Drug
Administration.
The presentation will be webcast live at:
http://customer.talkpoint.com/LEHM002/030806a_cs/default.asp?entity=Nabi
The webcast presentation will be available through April 3, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. The company has three products on the market today: PhosLo(R)
(calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and
Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is
focused on developing products that address unmet medical needs and offer
commercial opportunities in our core business areas: Gram-positive bacterial
infections, hepatitis, kidney disease (nephrology) and nicotine addiction.
For a complete list of pipeline products, please go to
http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca
Raton, Florida. For additional information about Nabi Biopharmaceuticals,
please visit our website at http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
Audio:http://customer.talkpoint.com/LEHM002/030806a_cs/default.asp?entity=Nabi
CONTACT:
Tom Rathjen, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
